B-control	0	9	Tamoxifen
O	10	16	versus
B-intervention	17	26	tamoxifen
I-intervention	27	31	plus
I-intervention	32	43	doxorubicin
I-intervention	44	47	and
I-intervention	48	64	cyclophosphamide
O	65	67	as
O	68	76	adjuvant
O	77	84	therapy
O	85	88	for
O	89	93	node
O	93	94	-
O	94	102	positive
O	103	117	postmenopausal
O	118	124	breast
O	125	131	cancer
O	131	132	:
O	133	140	results
O	141	143	of
O	144	145	a
O	146	151	Japan
O	152	160	Clinical
O	161	169	Oncology
O	170	175	Group
O	176	181	Study
O	182	183	(
O	183	191	JCOG9401
O	191	192	)
O	192	193	.

O	194	200	Cancer
O	201	208	subtype
O	209	212	has
O	213	221	recently
O	222	228	become
O	229	231	an
O	232	244	increasingly
O	245	254	important
O	255	268	consideration
O	269	273	when
O	274	282	deciding
O	283	286	the
O	287	296	treatment
O	297	305	strategy
O	306	309	for
O	310	316	breast
O	317	323	cancer
O	323	324	.

O	325	328	For
O	329	332	the
O	333	341	estrogen
O	342	350	receptor
O	351	359	positive
O	360	361	(
O	361	363	ER
O	363	364	+
O	364	365	)
O	366	373	subtype
O	373	374	,
O	375	378	the
O	379	387	efficacy
O	388	390	of
O	391	399	adjuvant
O	400	409	endocrine
O	410	417	therapy
O	418	420	is
O	421	431	definitive
O	431	432	,
O	433	436	but
O	437	441	that
O	442	444	of
O	445	453	adjuvant
O	454	466	chemotherapy
O	467	469	is
O	470	483	controversial
O	483	484	.

O	485	487	In
O	488	493	order
O	494	496	to
O	497	505	evaluate
O	506	509	the
O	510	516	effect
O	517	519	of
O	520	526	adding
O	527	538	doxorubicin
O	539	540	(
O	540	541	A
O	541	542	)
O	543	546	and
O	547	563	cyclophosphamide
O	564	565	(
O	565	566	C
O	566	567	)
O	568	570	to
O	571	580	tamoxifen
O	581	582	(
O	582	585	TAM
O	585	586	)
O	587	588	(
O	588	591	ACT
O	591	592	)
O	593	595	on
O	596	599	the
O	600	607	overall
O	608	616	survival
O	617	618	(
O	618	620	OS
O	620	621	)
O	622	624	of
B-eligibility	625	629	node
I-eligibility	629	630	-
I-eligibility	630	638	positive
I-eligibility	639	653	postmenopausal
I-eligibility	654	660	breast
I-eligibility	661	667	cancer
I-eligibility	668	669	(
I-eligibility	669	673	PMBC
I-eligibility	673	674	)
I-eligibility	675	683	patients
O	683	684	,
O	685	687	we
O	688	697	conducted
O	698	699	a
O	700	710	randomized
O	711	716	trial
O	716	717	.

O	718	729	Eligibility
O	730	738	criteria
O	739	747	included
O	748	762	pathologically
O	763	767	node
O	767	768	-
O	768	776	positive
O	777	778	(
O	778	779	n
O	780	781	=
O	782	783	1
O	783	784	-
O	784	785	9
O	785	786	)
O	787	791	PMBC
O	791	792	,
O	793	798	stage
O	799	800	I
O	800	801	-
O	801	805	IIIA
O	806	813	disease
O	813	814	.

O	815	823	Patients
O	824	828	were
O	829	839	randomized
O	840	842	to
O	843	850	receive
O	851	857	either
O	858	861	TAM
O	862	863	(
O	863	865	20
O	866	868	mg
O	869	874	daily
O	874	875	)
O	876	879	for
O	880	881	2
O	882	887	years
O	888	890	or
O	891	892	A
O	893	894	(
O	894	896	40
O	897	899	mg
O	899	900	/
O	900	901	m
O	901	902	(
O	902	903	2
O	903	904	)
O	904	905	)
O	906	909	and
O	910	911	C
O	912	913	(
O	913	916	500
O	917	919	mg
O	919	920	/
O	920	921	m
O	921	922	(
O	922	923	2
O	923	924	)
O	924	925	)
O	926	930	plus
O	931	934	TAM
O	935	936	(
O	936	939	ACT
O	939	940	)
O	941	943	as
O	944	952	adjuvant
O	953	960	therapy
O	961	970	following
O	971	978	surgery
O	978	979	.

B-total-participants	980	983	One
I-total-participants	984	991	hundred
I-total-participants	992	998	twenty
I-total-participants	998	999	-
I-total-participants	999	1003	nine
O	1004	1012	patients
O	1013	1017	were
O	1018	1027	recruited
O	1028	1029	(
O	1029	1032	TAM
B-control-participants	1033	1035	64
O	1035	1036	,
O	1037	1040	ACT
B-intervention-participants	1041	1043	65
O	1043	1044	)
O	1045	1052	between
O	1053	1060	October
O	1061	1065	1994
O	1066	1069	and
O	1070	1074	July
O	1075	1079	1999
O	1079	1080	.

O	1081	1084	The
O	1085	1091	hazard
O	1092	1098	ratios
O	1099	1102	for
B-outcome	1103	1105	OS
O	1106	1109	and
B-outcome	1110	1117	relapse
I-outcome	1117	1118	-
I-outcome	1118	1122	free
I-outcome	1123	1131	survival
I-outcome	1132	1133	(
I-outcome	1133	1136	RFS
I-outcome	1136	1137	)
O	1138	1142	were
O	1143	1144	0
O	1144	1145	.
O	1145	1147	58
O	1148	1149	(
O	1149	1151	95
O	1152	1153	%
O	1154	1156	CI
O	1157	1158	0
O	1158	1159	.
O	1159	1161	24
O	1161	1162	-
O	1162	1163	1
O	1163	1164	.
O	1164	1166	39
O	1166	1167	;
O	1168	1171	log
O	1171	1172	-
O	1172	1176	rank
O	1177	1178	p
O	1179	1180	=
O	1181	1182	0
O	1182	1183	.
O	1183	1185	22
O	1185	1186	)
O	1187	1190	and
O	1191	1192	0
O	1192	1193	.
O	1193	1195	45
O	1196	1197	(
O	1197	1199	95
O	1200	1201	%
O	1201	1203	CI
O	1204	1205	0
O	1205	1206	.
O	1206	1208	24
O	1208	1209	-
O	1209	1210	0
O	1210	1211	.
O	1211	1213	86
O	1213	1214	;
O	1215	1218	log
O	1218	1219	-
O	1219	1223	rank
O	1224	1225	p
O	1226	1227	=
O	1228	1229	0
O	1229	1230	.
O	1230	1233	013
O	1233	1234	)
O	1234	1235	,
O	1236	1248	respectively
O	1248	1249	,
O	1250	1252	in
O	1253	1258	favor
O	1259	1261	of
O	1262	1265	ACT
O	1265	1266	.

O	1267	1270	The
B-outcome	1271	1272	5
I-outcome	1272	1273	-
I-outcome	1273	1277	year
I-outcome	1278	1280	OS
O	1281	1284	and
B-outcome	1285	1288	RFS
O	1289	1293	were
B-cv-bin-percent	1294	1296	76
I-cv-bin-percent	1296	1297	.
I-cv-bin-percent	1297	1298	9
I-cv-bin-percent	1299	1300	%
O	1301	1302	(
O	1302	1304	ER
O	1304	1305	+
O	1306	1308	87
O	1308	1309	.
O	1309	1310	1
O	1311	1312	%
O	1312	1313	,
O	1314	1316	ER
O	1316	1317	-
O	1318	1320	53
O	1320	1321	.
O	1321	1322	3
O	1323	1324	%
O	1324	1325	)
O	1326	1329	and
B-cv-bin-percent	1330	1332	54
I-cv-bin-percent	1332	1333	.
I-cv-bin-percent	1333	1334	9
I-cv-bin-percent	1335	1336	%
O	1337	1338	(
O	1338	1340	ER
O	1340	1341	+
O	1342	1344	59
O	1344	1345	.
O	1345	1346	3
O	1347	1348	%
O	1348	1349	,
O	1350	1352	ER
O	1352	1353	-
O	1354	1356	42
O	1356	1357	.
O	1357	1358	9
O	1359	1360	%
O	1360	1361	)
O	1362	1365	for
O	1366	1369	TAM
O	1370	1373	and
B-iv-bin-percent	1374	1376	85
I-iv-bin-percent	1376	1377	.
I-iv-bin-percent	1377	1378	0
I-iv-bin-percent	1379	1380	%
O	1381	1382	(
O	1382	1384	ER
O	1384	1385	+
O	1386	1388	90
O	1388	1389	.
O	1389	1390	0
O	1391	1392	%
O	1392	1393	,
O	1394	1396	ER
O	1396	1397	-
O	1398	1400	77
O	1400	1401	.
O	1401	1402	1
O	1403	1404	%
O	1404	1405	)
O	1406	1409	and
B-cv-bin-percent	1410	1412	76
I-cv-bin-percent	1412	1413	.
I-cv-bin-percent	1413	1414	7
I-cv-bin-percent	1415	1416	%
O	1417	1418	(
O	1418	1420	ER
O	1420	1421	+
O	1422	1424	76
O	1424	1425	.
O	1425	1426	9
O	1427	1428	%
O	1428	1429	,
O	1430	1432	ER
O	1432	1433	-
O	1434	1436	76
O	1436	1437	.
O	1437	1438	0
O	1439	1440	%
O	1440	1441	)
O	1442	1445	for
O	1446	1449	ACT
O	1449	1450	.

O	1451	1452	A
O	1453	1459	higher
O	1460	1470	proportion
O	1471	1473	of
O	1474	1477	the
O	1478	1486	patients
O	1487	1496	receiving
O	1497	1500	ACT
O	1501	1505	than
O	1506	1511	those
O	1512	1521	receiving
O	1522	1525	TAM
O	1526	1537	experienced
O	1538	1543	grade
O	1544	1545	3
O	1546	1555	decreased
B-outcome	1556	1561	white
I-outcome	1562	1567	blood
I-outcome	1568	1572	cell
I-outcome	1573	1578	count
O	1579	1582	and
B-outcome	1583	1588	grade
I-outcome	1589	1590	2
I-outcome	1590	1591	-
I-outcome	1591	1592	3
I-outcome	1593	1599	nausea
O	1599	1600	.

O	1601	1604	The
O	1605	1613	efficacy
O	1614	1616	of
O	1617	1623	adding
O	1624	1626	AC
O	1627	1629	to
O	1630	1633	TAM
O	1634	1637	was
O	1638	1641	not
O	1642	1646	high
O	1647	1650	for
O	1651	1653	ER
O	1653	1654	+
O	1654	1655	,
O	1656	1660	node
O	1660	1661	-
O	1661	1669	positive
O	1670	1674	PMBC
O	1674	1675	.

O	1676	1683	However
O	1683	1684	,
O	1685	1693	adjuvant
O	1694	1697	ACT
O	1698	1705	therapy
O	1706	1709	was
O	1710	1720	considered
O	1721	1723	to
O	1724	1726	be
O	1727	1736	effective
O	1737	1740	for
O	1741	1743	ER
O	1743	1744	-
O	1744	1745	,
O	1746	1750	node
O	1750	1751	-
O	1751	1759	positive
O	1760	1764	PMBC
O	1764	1765	.
